Expressions of ER, PR, HER-2, COX-2, and VEGF in Primary and Relapsed/Metastatic Breast Cancers

Cell Biochemistry and Biophysics

Volumn 68, Issue 3, 2014, Pages 511-516

  Sun, Li ^a   Yu, Da hai ^b   Sun, San Yuan ^a   Zhuo, Shi Chao ^a   Cao, Su sheng ^a   Wei, Ling ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Breast cancer; Estrogen receptor; HER 2; Immunohistochemistry; Progestin receptor

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER; VASCULOTROPIN A;

ADULT; ARTICLE; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE;

ADULT; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896031911     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9729-y     Document Type: Article

References (23)

1. Coleman, M. P., Forman, D., Bryant, H., Butler, J., Rachet, B., Maringe, C., et al. (2011). Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet, 377, 127-138.
2. Wang, Q., Zhu, W., & Xing, X. (2006). The monitoring analysis of the mortality and morbidity of breast cancer patients in Beijing area. Chinese Journal of Oncology, 28, 208-211 (in Chinese).
3. Chen, K., He, M., & Dong, S. (2002). The monitoring analysis of the mortality and morbidity of breast cancer patients in Tianjin area. Chinese Journal of Oncology, 24, 573-575 (in Chinese).
4. Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., et al. (2010). American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Journal of Clinical Oncology, 28, 3784-3796.
5. Guideline Recommendations for HER2 Detection in Breast Cancer Group. (2009). Guidelines for HER2 detection in breast cancer, the 2009 version. Zhonghua Bing Li Xue Za Zhi, 38, 836-840 (in Chinese).
6. Early Breast Cancer Trialists' Collaborative Group. (1996). Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet, 348, 1189-1196.
7. Toft, D., & Gorski, J. (1966). A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proceedings of the National Academy of Sciences of the USA, 55, 1574-1581.
8. (2011). Breast cancer. NCCN clinical practice guidelines in Oncology. http://www. consensocancermamario. com/lib/files/documents/uploaded/NCCN2011_BC. pdf.
9. Franco, A., Col, N., Chlebowski, R. T. (2004). Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. Journal of Clinical Oncology, 22 Suppl 14, abstract 539.
10. Sari, E., Guler, G., Hayran, M., Altundag, K., Gullu, I., Ozisik, Y. (2009). Comparison of ER, PR, HER2 in primary and paired relapsed/metastatic lesions of metastatic breast cancer patients. Journal of Clinical Oncology, 27 Suppl 15, abstract 1063.
11. MacFarlane, R., Speers, C., Masoudi, H., Chia, S. (2008). Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. Journal of Clinical Oncology, 26 Suppl 15, abstract 1000.
12. Amir, E., Clemons, M., Freedman, O. C., Miller, N., Coleman, R. E., Purdie, C., Jordan, L., Quinlan, P., Thompson, A. M. (2010). Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. Journal of Clinical Oncology, 28 Suppl 15, abstract 1007.
13. Cardoso, F., Senkus-Konefka, E., Fallowfield, L., Costa, A., & Castiglione, M. (2010). Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(Suppl 5), v15-v19.
14. Wilking, U., Karlsson, E., Skoog, L., Hatschek, T., Lidbrink, E., Elmberger, G., et al. (2011). HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Research and Treatment, 125, 553-561.
15. Gutierrez, C., & Schiff, R. (2011). HER2: biology, detection, and clinical implications. Archives of Pathology and Laboratory Medicine, 135, 55-62.
16. Tonra, J. R., & Hicklin, D. J. (2007). Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunological Investigations, 36, 3-23.
17. Hicklin, D. J., & Ellis, L. M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23, 1011-1027.
18. Vidaurreta, M., Sanchez-Munoz, R., Veganzones, S., Rafael, S., Gutierrez, M., de la Orden, V., et al. (2010). Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Revista Espanola de Enfermedades Digestivas, 102, 20-31.
19. Boland, G. P., Butt, I. S., Prasad, R., Knox, W. F., & Bundred, N. J. (2004). COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. British Journal of Cancer, 90, 423-429.
20. Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., et al. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research, 62, 632-635.
21. Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proceedings of the National Academy of Sciences of the USA, 101, 591-596.
22. Cao, F., Gan, M., & Xie, B. (2008). The correlation between COX-2 and VEGF and hormone receptors in breast cancer. Chinese Oncology Prevention Treat, 15, 762-764 (in Chinese).
23. Pierga, J. Y., Delaloge, S., Espie, M., Brain, E., Sigal-Zafrani, B., Mathieu, M. C., et al. (2010). A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Research and Treatment, 122, 429-437.